# Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy

> **NCT00903851** · PHASE4 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** Lidoderm

## Key facts

- **NCT ID:** NCT00903851
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2003-06
- **Final completion:** —
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2010-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00903851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00903851, "Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00903851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*